Bambusa's BBT002 heads toward a safety readout in COPD patients by year-end
The Phase 1 trial testing Bambusa's IL-4Ralpha/IL-5 bispecific in COPD patients is a safety and tolerability study, not an efficacy trial, with topline data expected by December 31, 2026.
Executive Summary
- Bambusa Therapeutics is moving from healthy-volunteer testing of its IL-4Ralpha/IL-5 bispecific into a COPD patient cohort, with a safety and tolerability readout guided for the end of 2026.
- Preliminary healthy-volunteer data already showed the drug suppressing multiple Type 2 inflammation biomarkers for weeks after dosing, setting an operating expectation for what the patient cohort should reproduce.
- Because the trial is designed around adverse events, vital signs, and lab and ECG changes rather than a lung-function or exacerbation endpoint, the readout will speak to tolerability in a diseased population, not efficacy.
- No other industry trial pairs this target combination with COPD at any phase, leaving the asset without a same-mechanism comparator in this indication.
- The trial has kept its enrollment target and completion date stable since registration, with no protocol amendments recorded, a sign that execution is not yet in question.
The catalyst
Bambusa Therapeutics said it expects topline data from an ongoing proof-of-concept trial of BBT002 in COPD patients by year-end 2026, alongside a separate readout for a chronic rhinosinusitis trial expected in the first half of 2027. The COPD trial is registered as NCT07288554, a Phase 1 study enrolling both healthy volunteers and COPD patients in China, with an anticipated enrollment of 68 participants. The trial is Recruiting, started September 5, 2025, and carries a primary completion date of December 31, 2026, which sits inside the guided readout window. Bambusa+1Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026Jun 15, 2026A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07288554
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial measures
The registered primary endpoints are adverse events following single and multiple dosing, changes in 12-lead ECG readings, laboratory values, physical examination findings, and vital signs. Secondary endpoints cover pharmacokinetic parameters, including half-life, clearance, and volume of distribution, along with anti-drug antibody incidence. The design is a safety and pharmacokinetic study, not an efficacy trial: the COPD-patient cohort (Part B) requires a documented history of COPD with a post-bronchodilator FEV1/FVC ratio below 0.70 and FEV1 between 50% and 80% of predicted values, but the trial does not register a lung-function or exacerbation endpoint. NCT07288554A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07288554
What preceded this readout
Bambusa presented preliminary multiple-ascending-dose data from the healthy-volunteer portion of this same trial at the European Academy of Allergy & Clinical Immunology Congress on June 15, 2026. The company reported that BBT002 produced sustained depletion of eosinophils, dose-dependent reduction in the Type 2 inflammatory chemokine TARC, and inhibition of phosphorylated STAT6 for more than eight weeks after multiple doses, alongside a pharmacokinetic half-life of approximately 29.4 days. Thang Ho, the company's Chief Development Officer, said the data "further support BBT002 as a potentially differentiated, long-acting bispecific antibody targeting IL-4Ralpha and IL-5 to address multiple complementary drivers of Type 2 inflammation". The company also said BBT002 was well-tolerated across all doses tested in both the single- and multiple-ascending-dose cohorts. BambusaBambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026Jun 15, 2026
Competitive standing
No other industry trial combines the IL-4Ralpha and IL-5 targets in COPD at any phase, leaving BBT002 without a direct comparator on that specific mechanism pairing in this indication. The broader COPD field includes single-target biologics against related Type 2 inflammation pathways: Sanofi's itepekimab (anti-IL-33) is in a Phase 3 long-term safety study, AstraZeneca's tezepelumab is in two Phase 3 COPD trials, and GlaxoSmithKline's depemokimab, an IL-5-directed antibody, is in Phase 3 testing for COPD with Type 2 inflammation. None of these programs share BBT002's combined IL-4Ralpha/IL-5 targeting, so the readout will not be measured against a same-mechanism precedent.
Operational read
The trial's registry history shows a single event since its December 2025 registration, with no protocol amendments, no change in enrollment target, and no shift in the primary completion date. The enrollment target has held flat at 68 participants, which the operational risk model reads as within the routine band rather than a change requiring scrutiny. That stability, combined with a status of Recruiting rather than a slip to Unknown or a lapse in updates, points to a trial proceeding on its original design rather than one facing execution problems. NCT07288554A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07288554
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.